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The influence of different fibrates on apolipoprotein metabolism was investigated. Administration of fenoflbrate provoked a dose-dependent decrease in plasma cholesterol concentration that was already evident after 1 day. Intestinal apolipoprotein (apo) A-I and apo A-IV mRNA levels remained fairly constant In contrast, liver apo A-I, apo A-II, and apo A-IV mRNA levels decreased in a dose-dependent fashion, which was associated with a lower transcription rate of the apo A-I bat not the apo A-II gene. The decline in hepatic apo A-I, apo A-II, and apo A-IV mRNA had already started after 1 day and was associated with a drop in plasma apo A-I and apo A-IV concentrations. Plasma apo E had already decreased after 1 day of fenofibrate, whereas apo B initially remained constant and increased only after 14 days of fenofibrate at the highest dose. Hepatic and intestinal apo B mRNA contents and liver, heart, kidney, and testls apo E mRNA contents were only marginally affected after treatment with fenofibrate. liver low density lipoprotein receptor mRNA levels rose slightly after a 3-day administration of the highest dose of fenofibrate. Both clofibrate and gemfibrozil had effects comparable to those of fenofibrate on liver and intestinal apolipoprotein mRNA levels except for liver apo A-II mRNA, which decreased only marginally. Compared with fenofibrate, clofibrate caused similar changes in plasma cholesterol, apo A-I, apo A-IV, and apo E concentrations, whereas gemfibrozil increased plasma cholesterol and apo E without changing apo A-I and apo A-IV concentrations. In conclusion, all fibrates influence the expression of the apo A-I, apo A-II, and apo A-IV genes but not the apo B and apo E genes in a tissue-selective manner. After clofibrate and fenofibrate but not after gemfibrozil, these alterations are reflected by similar changes in plasma apolipoprotein concentrations. {Arteriosclerosis and Thrombosis 1992;12:286-294)
KEY WORDS • atherosclerosis • gene expression • hyperlipidemia • hypollpidemic drugs • steroid hormone receptors F ibrates are a class of hypolipidemic drugs widely used in the treatment of diet-resistant hyperlipidemia. In humans, fibrates decrease plasma triglyceride and/or cholesterol concentrations. 1 -5 In laboratory animals such as the rat, fibrates are extremely effective in lowering plasma cholesterol and' occasionally plasma triglyceride concentrations. 6 - 11 Although very little is known about the exact mechanism of action of these drugs, the decreases in plasma cholesterol and triglyceride levels are classically thought to be the result of a decrease in hepatic cholesterol synthesis 712 -14 and the induction of lipoprotein lipase in peripheral tissues, 15 -20 respectively. In addition, fibrates have been shown to be potent inducers of the /3-oxidation system of fatty acids in the liver and, to a lesser extent, in the intestine and kidney in rodents. 21 -24 These compounds act by inducing the expression of several genes that code for peroxisomal enzymes in the liver. 25 - 30 The induction of these enzymes results in a strong proliferation of peroxisomes and hepatomegaly and may ultimately lead to the development of hepatocarcinomas in animals treated for a prolonged period. 31 -32 Interestingly, a receptor activated by peroxisomal proliferators (such as fibrates) and belonging to the erb-A/steroid receptor gene superfamily has been recently cloned. 33 Receptors belonging to this family activate the transcription of ligand-inducible genes after binding as ligand-receptor complexes to specific DNA elements in the promotor region of genes. It is, therefore, tempting to speculate that fibrates might use a similar ligand-activated receptor to transmit their effect on gene expression.
In view of the strong effects of fibrates on lipoprotein metabolism, the aim of this study was to determine whether fibrates influence the expression of genes that code for proteins involved in lipoprotein metabolism, such as the different apolipoproteins or the low density lipoprotein (LDL) receptor, and whether the observed effects on plasma cholesterol and apolipoprotein concentrations could be explained by the alterations in gene expression in different tissues such as the liver or intestine. The results from these studies demonstrate that all fibrates tested affect the expression of the apo A-I, apo A-IV, and, to a lesser extent, the apo A-II genes in the liver but not the intestine. However, these effects on gene expression correlate with the pronounced decrease of the corresponding plasma apoh'poprotein concentrations only after clofibrate and fenofibrate but not after gemfibrozil administration.
Methods

Animals and Treatments
Male Wistar rats (90 days old) were treated for different periods of time with fenofibrate (Laboratoires Fournier, Daix, France), clofibrate (Sigma Chemical Co., St. Louis, Mo.), or gemfibrozil (Warner-Lambert Co., Ann Arbor, Mich.) mixed at the indicated concentrations (wt/wt) in standard rat chow. The food intake of the rats was recorded every 2 days throughout the treatment period. None of the treatments caused major changes in the amount of food consumed by the animals. Because each rat consumed approximately 20 g of chow per day, doses of 0.5%, 0.3%, 0.05%, and 0.005% fibrate ([wt/wt] mixed in rat chow) corresponded to 320, 190, 32, and 3 mg/kg body wt/day. At the end of the experiments, the animals were fasted overnight and killed at approximately 9 AM by exsanguination while under ether anesthesia. Blood was collected in EDTAcontaining tubes, and plasma was either used within 1 day for flotation of plasma lipoproteins or stored at -20°C for determination of cholesterol and apolipoprotein levels. Liver, heart, testis, and kidneys were removed immediately, rinsed with 0.9% saline, and frozen in liquid nitrogen. The intestine was removed and rinsed with ice-cold 0.9% saline, and the epithelium was scraped off and frozen in liquid nitrogen.
Measurement of Plasma Cholesterol and Apolipoprotein Concentrations
Plasma total cholesterol was measured as described previously. 34 Plasma apo A-I, apo A-IV, and apo E concentrations were measured by electroimmunoassay, exactly as described previously. 35 Plasma apo B was measured by radial immunodiffusion as described. 36 Total plasma lipoproteins were isolated by flotation through a potassium bromide gradient. 37 The lipoproteins obtained by flotation were ryophilized and then delipidated for 10 minutes at 95°C in 4% sodium dodecyl sulfate (SDS), and the apolipoproteins were separated by electrophoresis by SDS-poryacrylamide gel electrophoresis (PAGE) (15% resolving gel, 4% stacking gel). 38 Equal volumes of each sample were loaded to estimate relative changes in apolipoproteins. The different apolipoproteins were identified by comparing their mobility with purified apolipoproteins and by their apparent molecular weights. 38 
RNA Analysis
RNA was prepared by the guanidine isothiocyanate/ cesium chloride procedure from liver, kidney, heart, testis, and intestinal epithelium of individual animals. 39 Northern and dot-blot hybridizations of total cellular RNA were performed as described previously. 34 Care was taken to apply equal amounts of total RNA to all dot and Northern blot filters. The following apolipoprotein probes were used: a rat apo A-I cDNA probe 34 ; a rat apo A-II cDNA clone 40 ; a 42-base oligonucleotide probe constructed complementary to bases 73-114 of rat apo A-IV 37 ; a rat apo E cDNA clone 34 ; a rat 1.2-kb apo B cDNA probe 41 ; and a 0.3-kb BamYQ. restriction fragment of the human LDL receptor clone, pLDLR-3. 42 A chicken 0-actin cDNA clone 43 was used as a control. cDNA probes were labeled by nick translation (apo A-I, apo A-II, apo B, and apo E) or randomprimed labeling (/J-actin and LDL receptor; Boehringer Mannheim, Mannheim, FRG). Oligonucleotide probes (apo A-IV) were 5'-labeled using T4 polynucleotide kinase. Filters were hybridized to 1.5x10* cpm/ml of each probe as described. 34 They were washed in 500 ml of 0.5 x saline-sodium citrate buffer (SSC) and 0.1% SDS for 10 minutes at room temperature and twice for 30 minutes at 65°C and subsequently exposed to x-ray film (X-OMAT-AR, Kodak Co. Inc., Rochester, N.Y.). Autoradiograms were analyzed by quantitative scanning densitometry (LKB 2202 Ultrascan laser densitometer, LKB, Bromma, Sweden) as described. 34 None of the treatments caused significant changes in liver, intestinal, heart, testis, or kidney 0-actin mRNA levels, therefore indicating that the observed effects of fibrates on apolipoprotein gene expression are specific and not due to changes in the liver weights of the rats.
Isolation of Nuclei and Transcriptional Rate Assay
Nuclei were prepared from livers of untreated rats and from livers of rats treated for 14 days with fenofibrate (0.5% [wt/wt] in rat chow) exactly as described by Gorski et al. 44 Transcription run-on assays were performed as described by Nevins. 45 Equivalent amounts of labeled nuclear RNA were hybridized for 36 hours at 42°C to 5 fig of purified cDNAs immobilized on Hybond-C Extra filters (Amersham, Arlington Heights, 111.). The following cDNA probes were spotted: a rat apo A-I cDNA probe 34 ; a rat apo A-II cDNA clone 40 ; and a rat apo E cDNA clone. 34 As a control, 5 /xg of vector DNA was also applied to the filter. After hybridization, filters were washed at room temperature for 10 minutes in 0.5 x SSC and 0.1% SDS and twice for 30 minutes at 65°C and subsequently exposed to x-ray film (X-OMAT-AR, Kodak). Autoradiograms were analyzed by quantitative scanning densitometry (LKB 2202 Ultrascan laser densitometer).
Statistical Methods
Analysis of variance was used to evaluate the results of the dose-response and time-course experiments. If significance was attained, contrast statements were used to compare different dose and time groups. After checking whether variances were equal, the appropriate twotailed unpaired Student's t test was used to evaluate differences between means in experiments with clofibrate and gemfibrozil.
Results
Time-Dependent Effects of Fenofibrate
Administration of fenofibrate mixed at 0.5% (wt/wt) in rat chow caused a small decline in body weight after 7 and 14 days, whereas liver weights had already increased after 1 day and rose further after 3 and 7 days (Table 1) . Plasma cholesterol concentrations dropped Values represent mean±SD. Adult male rats (n=3) received fenofibrate (0.5% [wt/wt] mixed in rat chow) for the indicated periods of time. Body and liver weights were recorded at the end of the treatment period. Plasma cholesterol concentrations were measured as described in "Methods." Statistically significant differences (by analysis of variance;/? <0.05) are observed between values followed by different symbols.
maximally after 1 day of fenofibrate and remained fairly constant thereafter (Table 1) .
Hepatic apo A-I mRNA levels fell to less than 50% of control after 1 day of fenofibrate and decreased to less than 10% of control after 7 days ( Figure 1A ). In the liver, apo A-II mRNA levels had already dropped to less than one fourth ( Figure IB) , and apo A-IV mRNA levels fell to less than 20% of controls after 1 day of fenofibrate ( Figure 1C ). Intestinal apo A-I ( Figure 1A ) and apo A-IV ( Figure 1C ) mRNA levels, on the other hand, remained fairly constant throughout the treatment period. In plasma the concentrations of apo A-I and apo A-IV showed similar patterns: both apolipoproteins showed a maximal decrease after 3 days and remained low thereafter ( Figure ID) .
After 1 day of treatment with fenofibrate, liver apo B and apo E mRNA levels decreased slightly by approximately 25% (Figures 2A and 2B ). After 7 and 14 days, however, only apo B mRNA remained lower (Figure 2A ), whereas apo E mRNA levels returned to levels comparable to those before treatment ( Figure  2B ). Intestinal apo B mRNA levels were not significantly influenced during treatment (Figure 2A ). In plasma, apo E concentrations decreased after fenofiAdult male rats (n=3) were treated with the indicated dose (percent [wt/wt] in rat chow) of fenofibrate for 14 days. Body and liver weights were recorded at the end of the treatment period. Plasma cholesterol concentrations were measured as described in "Methods." Statistically significant differences (by analysis of variance;/?<0.05) are observed between values followed by different symbols.
brate, whereas apo B remained fairly constant during the first week and showed an increase after 14 days ( Figure 2D ). Hepatic LDL receptor mRNA rose nearly 50% after 3 days of fenofibrate and remained slightly elevated thereafter ( Figure 2C ).
Dose-Dependent Effects of Fenofibrate
The body weights of the animals decreased only at the highest dose of fenofibrate tested, whereas liver weights had already increased after treatment with an intermediate dose and showed a further rise at the highest dose (Table 2) . Plasma cholesterol concentrations tended to decrease at a dose of 0.005%, and a maximal effect was already attained at 0.05% fenofibrate ( Table 2) .
Hepatic apo A-I mRNA levels decreased in a dosedependent fashion, whereas intestinal apo A-I mRNA levels remained constant ( Figure 3A) . Treatment with fenofibrate maximally decreased liver apo A-II and apo A-IV mRNA levels at a dose of 0.05% (Figures 3B and  3Q . The changes in liver apo A-I and apo A-II mRNA levels, as observed after dot-blot hybridization, were confirmed after Northern blot hybridization (Figure 4) . Intestinal apo A-IV mRNA was not significantly influenced at any of the doses tested ( Figure 3C ). Plasma Animals and treatments were exactly as described in the legend to Figure 1 . Plasma apolipoprotein concentrations and liver mRNA levels were measured and expressed as described in "Methods." Results were expressed as described in the legend to Figure 1 . A. U., absorbance units.
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apo A-I and apo A-FV concentrations reflected the changes in hepatic mRNA levels and decreased in a dose-dependent manner ( Figure 3D ).
liver apo B mRNA levels decreased slightly after a dose of 0.05% fenofibrate, whereas intestinal apo B mRNA levels were not significantly influenced ( Figure  5A ). Fenofibrate did not influence liver apo E mRNA levels (Figures 4 and 5B) , whereas LDL receptor mRNA levels increased only after the highest dose tested ( Figure  5C ). In plasma, apo E concentrations had already dropped at an intermediate dose of fenofibrate, whereas apo B increased only at the highest dose tested ( Figure 5D ).
Influence of Fenofibrate on Hepatic Apolipoprotein A-I, Apolipoprotein A-II, and Apolipoprotein E Gene Transcription Rates
To determine whether the decrease in liver apo A-I and apo A-II mRNA levels was a consequence of a decrease in mRNA synthesis rates, nuclear run-on experiments were performed on nuclei prepared from livers of untreated control rats or rats treated with fenofibrate (0.5% [wt/wt]) for 14 days. The transcription rate of the apo A-I gene decreased approximately 10-fold in livers from rats treated with fenofibrate compared with control livers (Figure 6 ). In contrast, hepatic apo A-II gene transcription did not change at all after fenofibrate treatment, whereas hepatic apo E gene transcription decreased slightly after fenofibrate ( Figure 6 ).
Influence of Fenofibrate on Extrahepatic Apolipoprotein E Gene Expression
Because treatment with fenofibrate lowered plasma apo E concentrations drastically without having major effects on liver apo E gene expression, it was investigated whether changes in extrahepatic apo E gene 46 The localization of the 18S and 28S rRNAs are indicated on the autoradiograph expression contributed to the observed effects on plasma apo E concentrations. Administration of fenofibrate produced a small but statistically significant decrease in testis and kidney apo E mRNA content, whereas heart apo E mRNA levels remained unchanged (Table 3) . A small decrease in kidney apo E mRNA levels was observed after 7 days of fenofibrate (Table 4) , whereas testis apo E mRNA levels decreased only after 14 days. However, the overall time-dependent effect was not statistically significant because of the large variation of the response after 1 day of treatment.
FIGURE 3. Line plots showing the influence of treatment with different doses of fenofibrate on liver and intestinal apolipoprotein (apo) A-I (panel A), apo A-II (panel B), and apo A-IV (panel C) mRNA levels and on plasma apo A-I and apo A-IV concentrations (panel D). Adult male rats were treated for 14 days with the indicated doses of fenofibrate (wt/wt, mixed in rat chow
Influence of Treatment With Clofibrate and Gemfibrozil on Lipid and Apolipoprotein Parameters
Finally, it was investigated whether the effects observed after treatment with fenofibrate were general effects of fibrates or whether they were limited to fenofibrate only. Therefore, male rats were treated with either one of two other fibrates, clofibrate or gemfibrozil. Administration of clofibrate or gemfibrozil did not influence the body weights of the animals, whereas liver weights increased to an extent similar to that observed after treatment with fenofibrate at a dose of 0.05%-0.5% (Tables 2, 5 , and 6).
Treatment with clofibrate reduced plasma cholesterol levels to 50% of the concentrations in the control rats, and plasma apo A-I, apo A-IV, and apo E dropped to two thirds of controls (Table 5 ). These changes in plasma apolipoprotein levels, as measured by immunoassay, were confirmed after SDS-PAGE of lipoproteins obtained by flotation from plasma of control and clofibrate-treated rats (Figure 7) . Plasma apo B concentrations did not change significantly after clofibrate (Table 5 ). Liver apo A-I, apo A-II, and apo A-IV mRNA levels decreased after clofibrate, but the decrease in apo A-II mRNA was much less pronounced than that after fenofibrate (Table 5) . Liver apo B, apo E, and LDL receptor mRNA levels and intestinal apo A-I, apo A-IV, and apo B mRNA levels were not significantly influenced by clofibrate (Table 5) .
In contrast, administration of gemfibrozil increased plasma cholesterol and apo E concentrations, whereas plasma apo A-I, apo A-IV, and apo B concentrations remained unchanged (Table 6 ). However, liver apo A-I and apo A-IV mRNA levels decreased to 30% and to less than 10% of controls, respectively, whereas liver apo A-II and apo B mRNA levels dropped only marginally (Table 6 ). Intestinal apo A-I and apo B mRNA levels remained unchanged, whereas intestinal apo A-IV and liver LDL receptor mRNA levels tended to increase, but the effect was not statistically significant because of the large variation in response between animals ( Table 6 ). Liver apo E mRNA levels did not change after gemfibrozil (Table 6) .
Discussion
At present, relatively little is known about the mechanism through which fibrates alter plasma lipid and
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FIGURE 5. Line plots showing the influence of treatment with different doses of fenofibrate on liver and intestinal apolipoprotein (apo) B (panel A), apo E (panel B), and low density lipoprotein (LDL) receptor (panel C) mRNA levels and on plasma apo B and apo E concentrations (panel D)
. Animals and treatments were exactly the same as described in the legend to Figure 1 . Plasma apolipoprotein concentrations and liver mRNA levels were measured and expressed as described in "Methods." Results were expressed as described in the legend to Figure 3. A. U., absorbance units. CON apolipoprotein concentrations. The results from these studies demonstrate for the first time that fibrates may act by selectively influencing the expression of genes involved in lipoprotein metabolism in the rat liver. On the one hand, apo A-I, apo A-IV, and, to a lesser extent, apo A-II mRNA levels decrease after administration of fibrates. This decrease in mRNA steady-state levels is associated with a lowered transcription rate for the apo A-I gene but not for the apo A-II gene. Therefore, the expression of the apo A-II gene appears to be regulated at a posttranscriptional level, which may contribute to the variation in response of the apo A-II gene observed after treatment with different fibrates. In addition, the differential effects of clofibrate and fenofibrate, as opposed to gemfibrozil, on plasma apolipoprotein concentration but not on apolipoprotein gene expression suggest that fibrates may differentially affect apolipoprotein production at a posttranscriptional or translational level.
On the other hand, apo E and apo B mRNA levels are only marginally affected by fibrates. However, plasma apo E decreases after clofibrate and fenofibrate but increases after gemfibrozil. This increase in plasma apo E after gemfibrozil is in agreement with previous observations of cholesterol-fed rats treated with this drug. 47 Several mechanisms can be invoked to explain the lowered plasma apo E levels after clofibrate and fenofibrate. First, the decrease in plasma apo E may reflect an increased clearance of apo E-containing lipoproteins from plasma by the LDL receptor, whose mRNA levels are slightly increased in fenofibratetreated liver. However, because the induction of LDL receptor gene expression trails the fall in plasma cholesterol and apo E levels by 2 days, it seems more likely that the pronounced decrease in plasma cholesterol causes an upregulation of LDL receptor gene expression instead of the opposite. Second, apo E production may be lowered. The decreased apo E gene expression in kidney and testis may contribute to the fall in plasma apo E concentrations. However, it is unlikely that the rather small decrease in apo E mRNA levels in these tissues is entirely responsible for this decrease, as the liver produces the majority of plasma apo E 48 and apo E gene expression is not affected in this organ. Finally, it is likely that apo E synthesis is regulated at posttranscriptional or translational levels by fibrates. Indeed, hepatic lipoprotein secretion has been shown to be decreased in rats treated with fenofibrate and ciprofibrate 7 and clofibrate has been shown to lower hepatic very low density lipoprotein production and triglyceride secretion, 9 -46 whereas gemfibrozil increases hepatic apo E synthesis and secretion. 49 The increased plasma apo B concentrations, along with the unchanged liver and intestinal apo B mRNA levels, are remarkable, as liver LDL receptor mRNA levels are elevated in fenofibrate-treated rats. These observations suggest that fenofibrate may influence apo B production at a cotranscriptional or a posttranscriptional level. At present, studies are being undertaken to determine whether this drug regulates liver and/or intestinal apo B mRNA editing.
In contrast to their effects on liver apolipoprotein gene expression, intestinal mRNA levels remain unchanged or change in the opposite direction after treatment with fibrates. These observations extend our previous studies that show that apolipoprotein gene expression is much more susceptible to regulation in the liver than in the intestine. 34 -3741 ' 50 Indeed, both liver apo A-I and apo A-IV gene expressions are regulated in a tissue-selective manner after treatment with several hormones, including corticosteroids, 50 thyroid hormones, 37 -41 and estrogens, 34 with the liver being much more responsive than the intestine. This suggests that the expression of apolipoprotein genes is constitutive in the intestine, whereas expression in the liver is more regulated.
Finally, because of the peroxisomal proliferation observed after fibrate administration in rodents, 21 " 24 liver weights increase dramatically. These observations raise the question as to whether the effects of fibrates on apolipoprotein gene expression are mediated via their effects on peroxisomal proliferation and, hence, liver weight. Several lines of evidence, however, argue against this possibility. First, the brisk onset (1 day) of the changes in apolipoprotein gene expression suggest that fibrates may act directly on apolipoprotein gene expression. Second, the decreased transcription rate of the apo A-I gene in isolated nuclei points to a direct effect of fenofibrate on the expression of this gene. Finally, £-actin mRNA levels and transcription rates remain unchanged after administration of fibrates.
In conclusion, these studies show that fibrates have major effects on the expression of selective apolipoprotein genes in the rat liver but not in the intestine. Furthermore, the distinct effects of fenofibrate, clofi- brate, and gemfibrozil on plasma apolipoprotein concentrations but not on liver apolipoprotein mRNA levels suggest that in addition to the effects of these drugs on gene expression, additional mechanisms appear to be operative. These observations warrant more detailed exploration of the effects of fibrates on gene expression in different animal species as well as in humans.
